Identification of a thermal degradation product of CUMYL-PEGACLONE and its detection in biological samples.
CUMYL-PEGACLONE
synthetic cannabinoids
thermal degradation
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
04
07
2019
revised:
13
08
2019
accepted:
16
08
2019
pubmed:
4
9
2019
medline:
27
2
2020
entrez:
4
9
2019
Statut:
ppublish
Résumé
The structural diversity of synthetic cannabinoids makes it a challenging task to have a comprehensive screening method for this class of drugs. The difficulty is increased by the fact that some synthetic cannabinoids undergo thermal decomposition during common routes of administration, such as smoking or vaping. CUMYL-PEGACLONE is a relatively new synthetic cannabinoid which has a structural variant from most other synthetic cannabinoids: a γ-carbolinone core. To investigate its thermal stability, CUMYL-PEGACLONE was heated in an oven at temperatures ranging from 200 to 350
Substances chimiques
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Designer Drugs
0
Illicit Drugs
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1480-1485Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
World Drug Report 2017. United Nations Office on Drugs and Crime, Vienna, Austria. 2017. https://www.unodc.org/wdr2017/field/Booklet_4_ATSNPS.pdf. Accessed 23 October, 2018.
Synthetic cannabinoids in herbal products. United Nations Office on Drugs and Crime (UNODC), Vienna, Austria. 2011. https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf. Accessed 21 February, 2019.
Monitoring the Future national survey results on drug use 1975-2018: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, University of Michigan. 2019. http://monitoringthefuture.org/pubs/monographs/mtf-overview2018.pdf. Accessed 11 February, 2019.
Ernst L, Langer N, Bockelmann A, Salkhordeh E, Beuerle T. Identification and quantification of synthetic cannabinoids in ‘spice-like' herbal mixtures: update of the German situation in summer 2018. Forensic Sci Int. 2019;294:96-102.
European Drug Report: Trends and Developments. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg. 2017. http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf. Accessed 21 February, 2019.
Current NPS Threats. United Nations Office on Drugs and Crime, Vienna, Austria. 2019. https://www.unodc.org/pdf/opioids-crisis/Current_NPS_Threats_-_Volume_I.pdf. Accessed 07 March, 2019.
Cooper ZD. Adverse effects of synthetic cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep. 2016;18(5):52.
Gundersen POM, Spigset O, Josefsson M. Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS. Drug Test Anal. 2019;11(1):51-67.
Wohlfarth A, Scheidweiler KB, Chen X, Liu H-f, Huestis MA. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC−MS/MS and library search. Anal Chem. 2013;85(7):3730-3738.
Yeter O. Identification of the synthetic cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1Hindazole-3-carboxamide (CUMYL-4CN-BINACA) in plant material and quantification in post-mortem blood samples. J Anal Toxicol. 2017;41(9):720-728.
Staeheli SN, Steuer AE, Kraemer T. Identification of urinary metabolites of the synthetic cannabinoid 5F-CUMYL-P7AICA in human casework. Forensic Sci Int. 2019;294:76-79.
Mogler L, Halter S, Wilde M, Franz F, Auwarter V. Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE. Forensic Toxicology. 2019;37(1):154-163.
Mogler L, Wilde M, Huppertz LM, Weinturtner G, Franz F, Auwarter V. Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. Drug Test Anal. 2018;10(5):886-891.
Angerer V, Franz F, Moosmann B, Bisel P, Auwarter V. 5F-Cumyl-PINACA in ‘e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicology. 2019;37(1):186-196.
Fort C, Jourdan T, Kemp J, Curtis B. Stability of synthetic cannabinoids in biological specimens: analysis through liquid chromatography tandem mass spectrometry. J Anal Toxicol. 2017;41(5):360-366.
Franz F, Angerer V, Brandt S, et al. In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability. Drug Test Anal. 2017;9(2):311-316.
Hess C, Krueger L, Unger M, Madea B. Freeze-thaw stability and long-term stability of 84 synthetic cannabinoids in serum. Drug Test Anal. 2017;9(10):1506-1511.
Kevin R, Kovach A, Lefever TW, et al. Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology. 2019;37(1):17-26.
Thomas BF, Lefever TW, Cortes RA, et al. Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences. J Pharmacol Exp Ther. 2017;361(1):162-171.
Kaizaki-Mitsumoto A, Hataoka K, Funada M, Odanaka Y, Kumamoto H, Numazawa S. Pyrolysis of UR-144, a synthetic cannabinoid, augments an affinity to human CB1 receptor and cannabimimetic effects in mice. J Toxicol Sci. 2017;42(3):335-341.
Halter S, Angerer V, Röhrich J, et al. Cumyl-PEGACLONE: a comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Drug Test Anal. 2019;11(2):347-349.
Aknouche F, Ameline A, Richeval C, et al. Testing for SGT-151 (CUMYL-PEGACLONE) and its metabolites in blood and urine after surreptitious administration. J Anal Toxicol. 2019; Special Issue:1-6.
Angerer V, Mogler L, Steitz J-P, et al. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid 'CUMYL-PEGACLONE'. Drug Test Anal. 2018;10(3):597-603.
Partridge E, Trobbiani S, Stockham P, Scott T, Kostakis C. A validated method for the screening of 320 forensically significant compounds in blood by LC/QTOF, with simultaneous quantification of selected compounds. J Anal Toxicol. 2018;42(4):220-231.
General Accreditation Guidance - Validation and verification of quantitative and qualitative test methods. National Association of Testing Authorities Australia, 2018. https://www.nata.com.au/phocadownload/gen-accreditation-guidance/Validation-and-Verification-of-Quantitative-and-Qualitative-Test-Methods.pdf. Accessed 04 June, 2019.
Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165(2-3):216-224.
Khajuria RK, Sharma N, Koul JL, Verma MK. Concentration dependent electrospray ionisation mass spectrometry and tandem mass spectrometry (MS/MS) studies on (E,E)-1-[5-(1,3-benzodioxol-5yl)-1-oxo-2,4-pentadienyl]- piperidine (Piperine) and its analogues. SpringerPlus. 2013;2(1):427-434.
Franz F, Angerer V, Hermanns-Clausen M, Auwarter V, Moosmann B. Metabolites of synthetic cannabinoids in hair--proof of consumption or false friends for interpretation? Anal Bioanal Chem. 2016;408(13):3445-3452.
Baker RR. Temperature distribution inside a burning cigarette. Nature. 1974;247(5440):405-406.
Chen W, Wang P, Ito K, et al. Measurement of heating coil temperature for e-cigarettes with a "top-coil" clearomizer. PloS One. 2018;13(4):e0195925-e0195925.